| Ytd | 3.33% | |
| 1y | -55.71% |
| Open | 0.23 | Prev Close | 0.23 | Low | 0.21 | High | 0.23 | Mkt Cap | 9.96M |
| Vol | 488.34K | Avg Vol | 525.96K | EPS | 0.73 | P/E | 0.30 | Forward P/E | -0.07 |
| Beta | 1.34 | Short Ratio | 0.03 | Inst. Own | 21.21% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 0.23 | 200-d Avg | 0.24 | 1yr Est | 90.50 |
TOVX News
Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(0.07) per share which missed the analys
Trial is entitled "A Phase IIa, single-arm, single-center, open-label, proof-of-concept trial ev
Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) stock increased by 98.9% to $83.59 during Tuesday&#
– Prolonged overall survival (OS) was observed in heavily pre-treated refractory Head & Neck Squ
Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(0.05) per share which met the analyst c
Amazon Inc (NASDAQ: AMZN) rose in pre-market trading after announcing a strategic collaboration with
Theriva Biologics Inc. shares are trading higher Monday after announcing upcoming poster on VIRAGE p
TopBuild Corp (NYSE: BLD) rises in pre-market trading after QXO (NYSE: QXO) agrees to acquire for $1
- Tumor reponse, biomarker, and subgroup analyses from the VIRAGE Phase 2b clinical trial support a
Maxim Group analyst Jason McCarthy upgrades Theriva Biologics (AMEX:TOVX) from Hold to Buy and an
Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeuti
Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(0.12) per share which beat the analyst
- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory
U.S. stock futures advanced on Friday following Thursday's record advances. Futures of major ben
US stock futures up, Actelis Networks, XCel Brands, Rumble Inc. up after hours. Theriva Biologics to